Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Potential for a More Personalized Approach to Womb Cancer

By Drug Discovery Trends Editor | May 8, 2015

Manchester doctors have helped show that high-risk womb cancer patients can be genetically profiled to allow them to receive more appropriate treatment.

Traditionally, patients with endometrial cancer – cancer of the womb lining – have their disease risk classified using a combination of clinical and tissue characteristics, including their age and the growth and invasion of their tumor.

Around 15-20 percent of patients have high-risk disease, but it is unclear what the best treatment approach is for these patients. Now Manchester researchers have investigated genetic alterations in high-risk endometrial cancer, to see if they could be used to create tumor subtypes.

Richard Edmondson, Professor of Gynaecological Oncology at The University of Manchester and Saint Mary’s Hospital, said: “Previous work, using comprehensive genetic profiling, has suggested that endometrial cancer can be classified into four subtypes. Our study has explored whether it is possible to use a simpler approach to detect subgroups in high risk patients.”

Using routinely available technology, the international TransPORTEC research consortium analysed samples from 116 patients with endometrial cancer to look for genetic variations.

The team, which also included Dr Emma Crosbie and Professor Henry Kitchener from Manchester, found that genetic subtypes existed in their group of patients, and that they could use their classification to predict which patients were more likely to relapse.

In addition, the analysis allowed them to identify distinctive genetic mutations that can be targeted with specific anti-cancer drugs.

“It looks like these cancers classed as ‘high-risk’ in fact vary significantly in outcome. Our results could be used to refine risk assessment for endometrial cancer patients and allow doctors to choose either a less aggressive approach or more targeted treatment for individual patients,” added Professor Edmondson.

Source: Manchester University


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

New cell imaging method reveals hidden enzyme activity 
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE